Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus KLOROMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus KLOROMIN.
K-LEASE vs KLOROMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
KLOROMIN is a potassium-sparing diuretic that acts by antagonizing aldosterone in the distal renal tubules, inhibiting sodium reabsorption and potassium excretion.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
1 g IV every 6 hours; infuse over 30 minutes.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extends to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 50 hours in severe impairment (CrCl <30 mL/min).
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Primarily renal (60-70% as unchanged drug, 10-20% as glucuronide conjugate), biliary/fecal (10-15% as metabolites).
Category C
Category C
Potassium Supplement
Potassium Supplement